Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured


      A total of 23 state Medicaid programs continue to restrict hepatitis C virus (HCV) medication access by liver disease or substance-use criteria, creating obstacles to HCV elimination and significant care disparities. Because public insurers often set precedents for private insurer coverage and clinician practice patterns, this study sought to analyze whether spillover occurs from state Medicaid HCV treatment restrictions to HCV screening and treatment rates in commercially insured individuals.


      Investigators analyzed 2014‒2017 commercial claims data across 48 U.S. states (721,961,965 person-months) and used an interrupted times series design to compare hepatitis C virus screening and treatment rates before and after state Medicaid HCV treatment policy changes, adjusting for state-level random effects, Medicaid expansion status, and state drug overdose incidence rates, in states that relaxed Medicaid policy over the study period. Analysis occurred during 2019‒2021.


      Hepatitis C virus screening rates among commercially insured individuals increased after the corresponding state Medicaid program relaxed HCV treatment policy. Among states that changed Medicaid policy, those that reduced fibrosis or both fibrosis and abstinence restrictions experienced increased HCV screening rates by the study end compared with states that changed only abstinence restrictions (rate ratio=1.29; 95% CI=1.15, 1.44; and rate ratio=1.32; 95% CI=1.17, 1.50, respectively). Similar patterns did not occur in HCV treatment rates, which declined after 2015 across groups.


      These data show that HCV screening rates increased among commercially insured individuals after the removal of Medicaid HCV treatment restrictions in the same state. This suggests that Medicaid treatment policies can spill over to affect health outcomes among commercially insured populations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hofmeister MG
        • Rosenthal EM
        • Barker LK
        • et al.
        Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.
        Hepatology. 2019; 69: 1020-1031
      1. Viral hepatitis surveillance - United States. Centers for Disease Control and Prevention. Updated August 7, 2020. Accessed April 9, 2021.

        • Chhatwal J
        • Chen Q
        • Bethea ED
        • Hur C
        • Spaulding AC
        • Kanwal F.
        The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States.
        Aliment Pharmacol Ther. 2019; 50: 66-74
        • Liao JM
        • Fischer MA.
        Restrictions of hepatitis C treatment for substance-using Medicaid patients: cost versus ethics.
        Am J Public Health. 2017; 107: 893-899
      2. Hepatitis C: state of Medicaid access. National Viral Hepatitis Roundtable, Center for Health Law and Policy Innovation. Updated January 1, 2022. Accessed July 21, 2021.

        • Center for Medicaid and CHIP Services, HHS
        Medicaid drug rebates program notice: assuring Medicaid beneficiaries access to hepatitis C (HCV).
        Center for Medicaid and CHIP Services, HHS, Baltimore, Maryland2015 ( Published November 5, 2015. Accessed June 26, 2021)
        • Kapadia SN
        • Jeng PJ
        • Schackman BR
        • Bao Y.
        State Medicaid hepatitis C treatment eligibility criteria and use of direct-acting antivirals.
        Clin Infect Dis. 2018; 66: 1618-1620
        • Wong RJ
        • Jain MK
        • Therapondos G
        • et al.
        Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
        Am J Gastroenterol. 2018; 113: 1329-1338
        • Younossi ZM
        • Bacon BR
        • Dieterich DT
        • et al.
        Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.
        J Viral Hepat. 2016; 23: 447-454
        • Mukka M
        • Akram S
        • Koirala J.
        Impact of Insurance and Treatment Regimens on HCV Outcome: longterm follow up study.
        2017 (Poster Presentation presented at the: IDWeek; San Diego, CA; October 5. Accessed May 17, 2021)
        • Harris AM
        • Khan MA
        • Osinubi A
        • Nelson NP
        • Thompson WW.
        Hepatitis C treatment among commercially or Medicaid-insured individuals, 2014-2018.
        Am J Prev Med. 2021; 61: 716-723
      3. United States District Court Southern District of Florida Miami Division, case no.: 15-cv-61144-RLR, Document 153 Class Action Settlement Final Approval Order and Judgement; 2017. Accessed March 25, 2021.

      4. Two Florida lawsuits win class-action settlements for hepatitis C coverage.
        Hep. 2017; (December 14. Accessed March 25, 2021)
        • Ramey C.
        New York insurers to change coverage of hepatitis C drugs.
        Wall Street Journal. 2016; (April 26. Accessed February 28, 2019)
        • Gowda C
        • Lott S
        • Grigorian M
        • et al.
        Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a national specialty pharmacy cohort study.
        Open Forum Infect Dis. 2018; 5ofy076
        • Landon BE.
        Tipping the scale - the norms hypothesis and physician behavior.
        N Engl J Med. 2017; 376: 810-811
        • Chambers JD
        • Chenoweth M
        • Thorat T
        • Neumann PJ.
        Private payers disagree with Medicare over medical device coverage about half the time.
        Health Aff (Millwood). 2015; 34: 1376-1382
      5. Chambers JD, Kim DD, Pope EF, Graff JS, Wilkinson CL, Neumann PJ. Specialty drug coverage varies across commercial health plans in the U.S. Health Aff (Millwood). 2018;37(7):1041‒1047.

        • Phillips KA.
        Evolving payer coverage policies on genomic sequencing tests: beginning of the end or end of the beginning?.
        JAMA. 2018; 319: 2379-2380
        • Phillips KA
        • Trosman JR
        • Weldon CB
        • Douglas MP.
        New Medicare coverage policy for next-generation tumor sequencing: a key shift in coverage criteria with broad implications beyond Medicare.
        JCO Precis Oncol. 2018; 2 (PO.18.00206)
      6. National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation. Hepatitis C: the state of Medicaid access; 2017 National summary report. October. Accessed August 2, 2018.

        • Alaska Department of Health and Social Services
        DUR meeting minutes.
        Alaska Department of Health and Social Services, Juneau, AL2017 ( Published September 15, 2017. Accessed September 16, 2019)
        • Toubman S.
        Legal threats to Connecticut removes HCV restrictions.
        National AIDS Treatment Advocacy Project, New York, NY2015 ( Published 2015. Accessed September 11, 2021)
        • Rini J.
        State changes hep C medication guidelines, avoids lawsuit.
        Delaware. 2016; (June 7. Accessed September 11, 2021)
        • Government of District of Columbia Department of Health Care Finance
        Initial prior authorization request Harvoni.
        Government of District of Columbia Department of Health Care Finance, Washington, DC2016 ( Published 2016. Accessed September 11, 2021)
        • Bruen BK.
        Assessing the past, present, and future of treatment of hepatitis C in the D.C. Medicaid population. ProQuest dissertations & theses global.
        The George Washington University, Washington, DC2019 ( Published May 19, 2019. Accessed September 11, 2021)
        • Maine Department of Health and Human Services
        Maine DUR Board Meeting minutes from September 11, 2018.
        Maine Department of Health and Human Services, Augusta, ME2018 ( Published August 14, 2018. Accessed September 11, 2021)
        • Maryland Department of Health
        2017 Joint chairmen's report (p. 87) - report on criteria used for individuals to be eligible for new therapies used for hepatitis C treatment.
        Maryland Department of Health, Baltimore, MD2018 ( Published January 24, 2017. Accessed September 11, 2021)
        • Center for Medicaid and Medicare Services
        Expansion of hepatitis C drug coverage in Massachusetts.
        Center for Medicaid and Medicare Services, Baltimore, MD2016 ( Published July 30, 2016. Accessed September 12, 2021)
      7. Michigan improves access to hepatitis C Treatment for Medicaid and Healthy Michigan Plan patients - hepatitis C: state of Medicaid access.
        National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation, Washington, DC2021 ([press release] Published 2021. Accessed May 3, 2021)
      8. Michigan Medicaid now covers hepatitis C treatment.
        Hep. March 10, 2016; ( Accessed September 12, 2021)
        • Howatt G.
        Minnesota takes step toward broader use of highly-effective hepatitis C treatment.
        Star Tribune, June 13, 2019 ( Accessed September 12, 2021)
        • Mississippi Division of Medicaid
        Pharmacy prior authorization information.
        Mississippi Division of Medicaid, Jackson, MS2016 ( Published October 3, 2016. Accessed September 11, 2021)
      9. Bough SA. United States district court Western District of Missouri Central Division. JEM. v. Kinkade - Order Denying Motion for Preliminary Injunction. Published 2017. Accessed September 11, 2021.

      10. Nebraska improves access to hepatitis C treatment for Medicaid patients.
        National viral hepatitis roundtable, Washington, DC2021 ([press release]. Published 2021. Accessed September 12, 2021)
      11. State of New Jersey, Department of Human Services, Division of Medical Assistance & Health Services. 2018 Newsletter: NJ FamilyCare Coverage of Hepatitis C Treatment. Accessed May 3, 2021.

        • Collaboratively expanded chronic HCV Medicaid treatment coverage
        NEJM Catalyst.
        February 13, 2019 ( Accessed August 26, 2019)
        • Hughes C.
        New York Medicaid to cover hepatitis C treatment.
        Times Union, April 27, 2016 ( Accessed March 1, 2019)
        • North Dakota Department of Human Services
        North Dakota Medicaid preferred drug list with prior authorization criteria.
        North Dakota Department of Human Services, Bismarck, ND2018 ( Published 2018. Accessed September 11, 2021)
        • Oregon Health Authority
        Official Website notice: recommendations of drug use review/Pharmacy and Therapeutics Committee.
        Oregon Health Authority, Salem, OR2018 ( Published December 12, 2018. Accessed September 11, 2021)
        • Oregon Health Authority
        Official Website notice: recommendations of drug use review/Pharmacy and Therapeutics Committee.
        Oregon Health Authority, Salem, OR2018 ( Published October 18, 2018. Accessed September 11, 2021)
        • Gordon E.
        Pennsylvania's Medicaid eases restrictions on hepatitis C treatment.
        WHYY. August 17, 2015; ( Accessed September 12, 2021)
        • Kabiri M
        • Chhatwal J
        • Donohue JM
        • et al.
        Long-term disease and economic outcomes of prior authorization criteria for hepatitis C treatment in Pennsylvania Medicaid.
        Healthc (Amst). 2017; 5: 105-111
      12. Borkowski R. Health groups upgrade R. I. Hepatitis C Medicaid access to'A-. Providence Bus News. October 29, 2018. Accessed September 12, 2021.

      13. South Carolina Health Connections Medicaid. South Carolina pharmacy services PTM minutes. Published 2016. Accessed September 16, 2019.

      14. Hirschfeld P, In C Vt. Medicaid Policy could improve access to live-saving hepatitis C treatment. Vermont Public Radio. December 16, 2016. Accessed September 12, 2021.

      15. Medicaid review board lifts liver damage restriction on life-saving cures for Vermonters with hepatitis C. VTDigger. November 1, 2017. Accessed September 12, 2021.

        • Washington State Health Care Authority
        Washington apple health hepatitis C treatment policy.
        Washington State Health Care Authority, Olympia, WA2016 ( Published July 5, 2016. Accessed September 12, 2021)
        • State of West Virginia Department of Health and Human Resources Bureau for Medical Services
        Office of Pharmacy Services Prior Authorization Criteria: SOVALDI® (sofosbuvir).
        State of West Virginia Department of Health and Human Resources Bureau for Medical Services, Charleston, WV2016 ( Published January 1, 2016. Accessed March 21, 2022)
        • HHS Hepatitis C Medicaid Affinity Group
        Tackling hepatitis C in Wisconsin: state strategies case study.
        HHS, Washington, DC2020 ( Published 2020. Accessed September 11, 2021)
        • Moyer VA; U.S.
        Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2013; 159: 349-357
        • Smith BD
        • Morgan RL
        • Beckett GA
        • et al.
        Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945‒1965 [published correction appears in MMWR Recomm Rep. 2012;61(43):886].
        MMWR Recomm Rep. 2012; 61: 1-32
      16. Barocas JA, Wang J, White LF, et al. Hepatitis C testing increased among Baby Boomers following the 2012 change to CDC testing recommendations. Health Aff (Millwood). 2017;36(12):2142‒2150.

        • Kaiser Family Foundation
        Status of state Medicaid expansion decisions: interactive map.
        Kaiser Family Foundation, San Francisco, CA2022 ( Updated April 26, 2022. Accessed May 12, 2022)
      17. Drug overdose deaths. Centers for Disease Control and Prevention, National Center for Health Statistics. Updated June 4, 2018. Accessed August 9, 2020.

        • Saeed S
        • Strumpf E
        • Moodie EEM
        • et al.
        Eliminating structural barriers: the impact of unrestricted access on hepatitis C treatment uptake among people living with human immunodeficiency virus.
        Clin Infect Dis. 2020; 71: 363-371
        • Jain MK
        • Thamer M
        • Therapondos G
        • et al.
        Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period?.
        Hepatology. 2019; 69: 51-63
        • Owens DK
        • Davidson KW
        • et al.
        • U.S. Preventive Services Task Force
        Screening for hepatitis C virus infection in adolescents and adults: U.S. Preventive Services Task Force recommendation statement.
        JAMA. 2020; 323: 970-975
        • Schillie S
        • Wester C
        • Osborne M
        • Wesolowski L
        • Ryerson AB.
        CDC recommendations for hepatitis C screening among adults - United States, 2020.
        MMWR Recomm Rep. 2020; 69: 1-17
        • Yehia BR
        • Schranz AJ
        • Umscheid CA
        • Lo Re V 3rd
        The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.
        PLoS One. 2014; 9e101554
        • Trickey A
        • Fraser H
        • Lim AG
        • et al.
        Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: a modelling study.
        J Viral Hepat. 2019; 26: 1388-1403
      18. Medicaid enrollment data collected through MBES. Centers for Medicare & Medicaid Services. Updated June 1, 2020. Accessed June 3, 2021.